1 Lavanchy D. Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures[J]. J Viral Hepat, 2004, 11(2): 97-107.
[2]
2 Lu FM, Zhuang H. Management of hepatitis B in China[J]. Chin Med J (Engl), 2009, 122(1): 3-4.
[3]
3 Yeo W, Chan PK, Ho WM, et al. Lamivudine for the prevention of hepatitis B virus reactivation in hepatitis B s-antigen seropositive cancer patients undergoing cytotoxic chemotherapy[J]. J Clin Oncol, 2004, 22(5): 927-934.
[4]
4 Cheng AL, Hsiung CA, Su IJ, et al. Steroid-free chemotherapy decreases risk of hepatitis B virus (HBV) reactivation in HBV-carriers with lymphoma[J]. Hepatology, 2003, 37(6): 1320-1328.
6 Lau GK, Yiu HH, Fong DY, et al. Early is superior to deferred preemptive lamivudine therapy for hepatitis B patients undergoing chemotherapy[J]. Gastroenterology, 2003, 125(6): 1742-1749.
[7]
7 Kim JH, Bang YJ, Park BJ, et al. Hepatitis B virus infection and B-cell non-Hodgkin’s lymphoma in a hepatitis B endemic area: a case-control study[J]. Jpn J Cancer Res, 2002, 93(5): 471-477.
[8]
8 Chen MH, Hsiao LT, Chiou TJ, et al. High prevalence of occult hepatitis B virus infection in patients with B cell non-Hodgkin’s lymphoma[J]. Ann Hematol, 2008, 87(6): 475-480.
[9]
9 European Association For The Study Of The Liver. EASL clinical practice guidelines: management of chronic hepatitis B[J]. J Hepatol, 2009, 50(2): 227-242.
[10]
10 Weinbaum CM, Williams I, Mast EE, et al. Recommendations for identification and public health management of persons with chronic hepatitis B virus infection[J]. MMWR Recomm Rep, 2008, 57(RR/8): 1-20.
[11]
11 Yeo W, Chan PK, Zhong S, et al. Frequency of hepatitis B virus reactivation in cancer patients undergoing cytotoxic chemotherapy: a prospective study of 626 patients with identification of risk factors[J]. J Med Virol, 2000, 62(3): 299-307.
[12]
12 Lee R, Vu K, Bell CM, et al. Screening for hepatitis B surface antigen before chemotherapy: current practice and opportunities for improvement[J]. Curr Oncol, 2010, 17(6): 32-38.
[13]
13 Hwang J, Fisch M, Zhang H, et al. Predictors of hepatitis B screening among patients with cancer[J]. J Clin Oncol, 2011, 29(Suppl 4): 180.
15 Zurawska U, Hicks LK, Woo G, et al. Hepatitis B virus screening before chemotherapy for lymphoma: a cost-effectiveness analysis[J]. J Clin Oncol, 2012, 30(26): 3167-3173.
[16]
16 Wang Y, Luo XM, Yang D, et al. Testing for hepatitis B infection in prospective chemotherapy patients: a retrospective study[J]. World J Gastroenterol, 2013, 19(6): 923-930.
[17]
17 Hwang J, Fisch M, Zhang H, et al. Hepatitis B screening and positivity prior to chemotherapy[J]. J Clin Oncol, 2010, 28 (Suppl 15): 9008.
[18]
18 Méndez-Navarro J, Corey KE, Zheng H, et al. Hepatitis B screening, prophylaxis and re-activation in the era of rituximab-based chemotherapy[J]. Liver Int, 2011, 31(3): 330-339.
[19]
19 Wang F, Xu RH, Han B, et al. High incidence of hepatitis B virus infection in B-cell subtype non-Hodgkin lymphoma compared with other cancers[J]. Cancer, 2007, 109(7): 1360-1364.
[20]
20 Marcucci F, Mele A, Spada E, et al. High prevalence of hepatitis B virus infection in B-cell non-Hodgkin’s lymphoma[J]. Haematologica, 2006, 91(4): 554-557.
[21]
21 Liang X, Bi S, Yang W, et al. Reprint of: epidemiological serosurvey of hepatitis B in china: declining HBV prevalence due to hepatitis B vaccination[J]. Vaccine, 2013, 31(Suppl 9): J21-J28.
23 Ji D, Cao J, Hong X, et al. Low incidence of hepatitis B virus reactivation during chemotherapy among diffuse large B-cell lymphoma patients who are HBsAg-negative/ HBcAb-positive: a multicenter retrospective study[J]. Eur J Haematol, 2010, 85(3): 243-250.
[24]
24 Yeo W, Chan TC, Leung NW, et al. Hepatitis B virus reactivation in lymphoma patients with prior resolved hepatitis B undergoing anticancer therapy with or without rituximab[J]. J Clin Oncol, 2009, 27(4): 605-611.
[25]
25 Kusumoto S, Tanaka Y, Mizokami M, et al. Reactivation of hepatitis B virus following systemic chemotherapy for malignant lymphoma[J]. Int J Hematol, 2009, 90(1): 13-23.
[26]
26 Johnson P, Glennie M. The mechanisms of action of rituximab in the elimination of tumor cells[J]. Semin Oncol, 2003, 30(1 Suppl 2): 3-8.
[27]
27 Wilson WH, Gutierrez M, O’connor P, et al. The role of rituximab and chemotherapy in aggressive B-cell lymphoma: a preliminary report of dose-adjusted EPOCH-R[J]. Semin Oncol, 2002, 29 (Suppl 2): 41-47.
[28]
28 Ghetie MA, Bright H, Vitetta ES. Homodimers but not monomers of rituxan (chimeric anti-CD20) induce apoptosis in human B-lymphoma cells and synergize with a chemotherapeutic agent and an immunotoxin[J]. Blood, 2001, 97(5): 1392-1398.
[29]
29 Demidem A, Lam T, Alas S, et al. Chimeric anti-CD20 (IDEC-C2B8) monoclonal antibody sensitizes a B cell lymphoma cell line to cell killing by cytotoxic drugs[J]. Cancer Biother Radiopharm, 1997, 12(3): 177-186.
[30]
30 Evens AM, Jovanovic BD, Su YC, et al. Rituximab-associated hepatitis B virus (HBV) reactivation in lymphoproliferative diseases: meta-analysis and examination of FDA safety reports[J]. Ann Oncol, 2011, 22(5): 1170-1180.
[31]
31 Dong HJ, Ni LN, Sheng GF, et al. Risk of hepatitis B virus (HBV) reactivation in non-Hodgkin lymphoma patients receiving rituximab-chemotherapy: a meta-analysis[J]. J Clin Virol, 2013, 57(3): 209-214.
[32]
32 Tsutsumi Y, Tanaka J, Kawamura T, et al. Possible efficacy of lamivudine treatment to prevent hepatitis B virus reactivation due to rituximab therapy in a patient with non-Hodgkin’s lymphoma[J]. Ann Hematol, 2004, 83(1): 58-60.
[33]
33 Dai MS, Chao TY, Kao WY, et al. Delayed hepatitis B virus reactivation after cessation of preemptive lamivudine in lymphoma patients treated with rituximab plus CHOP[J]. Ann Hematol, 2004, 83(12): 769-774.
[34]
34 Wang YH, Fan L, Wang L, et al. Efficacy of prophylactic lamivudine to prevent hepatitis B virus reactivation in B-cell lymphoma treated with rituximab-containing chemotherapy[J]. Support Care Cancer, 2013, 21(5): 1265-1271.
[35]
35 Chen XQ, Peng JW, Lin GN, et al. The effect of prophylactic lamivudine on hepatitis B virus reactivation in HBsAg-positive patients with diffuse large B-cell lymphoma undergoing prolonged rituximab therapy[J]. Med Oncol, 2012, 29(2): 1237-1241.
[36]
36 Martyak LA, Taqavi E, Saab S. Lamivudine prophylaxis is effective in reducing hepatitis B reactivation and reactivation-related mortality in chemotherapy patients: a meta-analysis[J]. Liver Int, 2008, 28(1): 28-38.
[37]
37 Lau GK. Hepatitis B reactivation after chemotherapy: two decades of clinical research[J]. Hepatol Int, 2008, 2(2): 152-162.
